The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LBRX | N/A | N/A | N/A | +22% |
| S&P | +13.99% | +77.08% | +12.11% | +4% |
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.
No news articles found for Lb Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$81.00K | -1520.0% |
| Market Cap | $354.38M | 0.0% |
| Net Income | -$3,556.00K | 74.9% |
| EBITDA | -$5,165.00K | 67.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $269.74M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.94M | 0.0% |
| Short Term Debt | $730.00K | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -285.85% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22,480.00K | 0.0% |
| Operating Free Cash Flow | -$22,037.00K | 0.0% |
| Metric | Q3 2025 | YoY Change | |
|---|---|---|---|
| Price to Book | -6.87 | - | |
| Price to Tangible Book Value | -6.87 | - | |
| Enterprise Value to EBITDA | -17.17 | - | |
| Total Debt | $0.00K | $3.67M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
